Curanex Pharmaceuticals CURX
NASDAQ CURX
$4.71 -0.56 (-10.63%)
At close: Aug 21, 2026 · 4:00 PM EDT

Curanex Pharmaceuticals (CURX) Income from Continuing Operations (2024 - 2025)

Curanex Pharmaceuticals' (CURX) quarterly Income from Continuing Operations came in at 3092639.0 in Q4 2025, down 1014.65% YoY from 338121.45 in Q4 2024, and down 159.18% on a QoQ basis from 1193245.0 in Q3 2025.

Curanex Pharmaceuticals (CURX) Income from Continuing Operations (2024 - 2025) Analysis & Trends

Curanex Pharmaceuticals (CURX) has 2 years of Income from Continuing Operations data on file, last reported at 3092639.0 in Q4 2025.

  • Quarterly Income from Continuing Operations fell 1014.65% year-over-year to 3092639.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 4792647.0 (changed N/A YoY) and the FY2025 annual result came in at 5256435.0, down 961.59% from the prior year.
  • Income from Continuing Operations fell to 3092639.0 in Q4 2025, from 1193245.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 93295.0 in Q3 2024 to a low of 3092639.0 in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 482.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 164.49 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -174.37 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -13.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 81.49 Mn
10 Curanex Pharmaceuticals 6.02 Mn 1.02 Mn - -3.09 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -3.09 Mn
Sep 30, 2025 -1.19 Mn
Jun 30, 2025 -229,310.00
Dec 31, 2024 -277,453.00
Sep 30, 2024 -93,295.00